Our work also demonstrates that intermittent CAR signaling in vivo can prevent or reverse exhaustion and thereby enhance anti-tumor responses in liquid and solid tumor models independent of the CAR costimulatory domain (CD28 versus 4-1BB) or the propensity for tonic CAR signaling (CD19 binder versus GD2 binder). The gene discussed is CD28; the disease is neoplasm.